AstraZeneca agrees to acquire Alexion Pharmaceuticals, Inc. for US$39B

Date Closed

July 21, 2021

Lead Office

Toronto

Value

39.00 Billion USD

Jonathan Bitran On July 21, 2021, AstraZeneca closed its agreement with Alexion Pharmaceuticals, Inc. to acquire Alexion for a total consideration of US$39 billion in cash and stock. The deal was undertaken through a US statutory merger. Upon completion, Alexion shareholders own approximately 15% of the combined company.

The acquisition will be financed in part by bridge financing provided by Morgan Stanley, J.P. Morgan Securities plc and Goldman Sachs.

AstraZeneca is a global biopharmaceutical company, based in the UK, that focuses on treatments and medical advancements in Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

McCarthy Tétrault advised AstraZeneca as Canadian competition counsel with a team led by Jason Gudofsky that included Casey Halladay and Jonathan Bitran (Competition) and Lisa Melanson (Regulatory).

People